AstraZeneca PLC

AZN

Company Profile

  • Business description

    A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

  • Contact

    1 Francis Crick Avenue
    Cambridge Biomedical Campus
    CambridgeCB2 0AA
    GBR

    T: +44 2037495000

    E: [email protected]

    https://www.astrazeneca.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    94,300

Stocks News & Analysis

markets

What are emerging and frontier markets?

Power blocs, frontier stocks and investor shocks explained as the world becomes more complex 
stocks

Magnificent Seven vs. the ‘Granolas’: How does Europe’s version stack up?

‘Granolas’ stocks are profitable, diversified, cheap—and posting big returns.
stocks

Best international companies to own: 2023 Edition

These companies from various corners of the globe are well positioned for the future.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,611.7038.300.45%
CAC 407,910.4931.93-0.40%
DAX 4024,122.4086.290.36%
Dow JONES (US)41,877.81799.43-1.87%
FTSE 1008,786.465.340.06%
HKSE23,827.78146.300.62%
NASDAQ18,888.37254.35-1.33%
Nikkei 22537,298.98230.51-0.61%
NZX 50 Index12,703.1058.870.47%
S&P 5005,848.3092.16-1.55%
S&P/ASX 2008,386.8043.500.52%
SSE Composite Index3,387.577.100.21%

Market Movers